궤양성 대장염 시장 기회, 성장요인, 업계 동향 분석 및 예측(2026-2035년)

The Global Ulcerative Colitis Market was valued at USD 8.3 billion in 2025 and is estimated to grow at a CAGR of 5.8% to reach USD 14.5 billion by 2035.

The market is expanding as the prevalence of ulcerative colitis continues to rise worldwide. Factors such as rapid urban development, lifestyle shifts, dietary changes, and environmental influences are contributing to a growing number of inflammatory bowel disease cases, including ulcerative colitis. Alongside this rising incidence, improved disease awareness among both healthcare professionals and patients is encouraging earlier detection and timely treatment. Early diagnosis allows healthcare providers to initiate appropriate therapies sooner, which supports better disease management and increases demand for pharmaceutical treatments. Continuous progress in treatment innovation is also shaping the market landscape by introducing more effective therapeutic approaches. Advances in diagnostic technologies, including modern imaging techniques, endoscopic procedures, and improved biomarker identification, have strengthened clinical evaluation and disease monitoring. In addition, the expansion of healthcare funding across both developed and emerging economies is improving access to advanced medical therapies. These developments are enabling healthcare systems to adopt newer treatment options and support broader patient access, which continues to drive the long-term growth of the ulcerative colitis market.

The development of advanced therapeutic options has played a major role in transforming ulcerative colitis treatment strategies. The introduction of targeted therapies has significantly expanded available treatment choices for patients experiencing moderate to severe disease conditions. These innovative therapies are designed to regulate immune system activity and reduce inflammation more effectively than traditional medications. At the same time, improvements in diagnostic technologies have strengthened early disease detection and clinical monitoring. Enhanced diagnostic tools allow healthcare providers to assess disease progression more accurately and initiate treatment earlier in the disease cycle. As a result, the combined use of conventional medications and advanced treatment approaches is improving long-term disease management while contributing to increased utilization of ulcerative colitis therapies worldwide.

The oral segment accounted for 52% share in 2025. This segment continues to demonstrate strong growth due to the convenience and accessibility associated with oral medications. Many patients prefer oral therapies because they are easier to administer and do not require invasive procedures. These medications are commonly used for long-term disease management and are considered a practical treatment option across different stages of the condition. Continuous improvements in drug formulation technologies have further enhanced the effectiveness of oral medications. Innovations such as controlled-release and targeted delivery mechanisms are improving treatment performance while also increasing patient tolerance and adherence, which supports the growing adoption of oral therapies.

The hospital pharmacies segment is projected to grow at a CAGR of 5.6% during 2026-2035. Hospital pharmacies play a vital role in distributing complex treatment regimens and ensuring safe medication administration. Healthcare professionals within hospital settings closely monitor patients receiving advanced therapies to manage potential side effects and optimize treatment outcomes. The increasing number of hospital admissions related to ulcerative colitis complications is further strengthening the importance of hospital pharmacies in treatment delivery. In addition, integration between hospital pharmacies and healthcare providers helps support coordinated care, improving treatment management and patient outcomes. Greater access to insurance coverage and reimbursement programs also enables hospital pharmacies to provide patients with access to high-cost therapies, contributing to their leading position in the market.

North America Ulcerative Colitis Market accounted for 41.2% share and is expected to grow at a CAGR of 5.6% throughout 2035. The region benefits from a well-developed healthcare infrastructure, strong accessibility to advanced treatment options, and widespread insurance coverage that supports the use of modern therapies. Early diagnosis and increased awareness among healthcare professionals and patients also contribute to higher treatment adoption rates. Furthermore, North America serves as a major center for pharmaceutical innovation, where new therapies and treatment technologies are frequently introduced. Ongoing research activities, clinical studies, and patient support initiatives conducted by major pharmaceutical companies are further strengthening the market and supporting continued growth across the region.

Major companies operating in the Global Ulcerative Colitis Market include Pfizer, AbbVie, Takeda Pharmaceutical Company Limited, Johnson & Johnson, Bristol Myers Squibb, Novartis, Eli Lilly and Company, Merck, Sun Pharmaceutical Industries, Mitsubishi Tanabe Pharma Corporation, Bausch Health Companies, and Teva Pharmaceutical Industries. Companies competing in the Global Ulcerative Colitis Market are implementing a range of strategies to strengthen their competitive positions and expand their global presence. Leading pharmaceutical organizations are investing heavily in research and development to introduce innovative therapies that improve disease management and patient outcomes. Many companies are also focusing on expanding their product pipelines through clinical trials and regulatory approvals for advanced treatment options. Strategic collaborations with biotechnology firms, research institutions, and healthcare providers are helping accelerate drug discovery and development processes. In addition, companies are expanding their geographic reach through global distribution networks and market entry strategies in emerging healthcare markets.

Table of Contents

Chapter 1 Research Methodology

• 1.1 Market scope and definition
• 1.2 Research approach
• 1.3 Quality commitments
  • 1.3.1 GMI AI policy & data integrity commitment
    • 1.3.1.1 Source consistency protocol
• 1.4 Research trail & confidence scoring
  • 1.4.1 Research trail components
  • 1.4.2 Scoring components
• 1.5 Data collection
  • 1.5.1 Partial list of primary sources
• 1.6 Data mining sources
  • 1.6.1 Paid sources
    • 1.6.1.1 Sources, by region
• 1.7 Base estimates and calculations
  • 1.7.1 Base year calculation for any one approach
• 1.8 Forecast model
  • 1.8.1 Quantified market impact analysis
    • 1.8.1.1 Mathematical impact of growth parameters on forecast
• 1.9 Research transparency addendum
  • 1.9.1 Source attribution framework
  • 1.9.2 Quality assurance metrics
  • 1.9.3 Our commitment to trust

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis
• 2.2 Key market trends
  • 2.2.1 Drug type trends
  • 2.2.2 Disease type trends
  • 2.2.3 Route of administration trends
  • 2.2.4 Distribution channel trends
• 2.3 CXO perspectives: Strategic imperatives

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence of ulcerative colitis
    • 3.2.1.2 Expanding treatment options
    • 3.2.1.3 Increasing awareness and diagnosis
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 High treatment costs
    • 3.2.2.2 Side effects and safety concerns
  • 3.2.3 Market opportunities
    • 3.2.3.1 Growing demand and utilization of combination therapies
    • 3.2.3.2 Development of pediatric ulcerative colitis treatment
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape (Driven by primary research)
  • 3.4.1 North America
    • 3.4.1.1 U.S.
    • 3.4.1.2 Canada
  • 3.4.2 Europe
  • 3.4.3 Asia Pacific
• 3.5 Pricing analysis (Driven by primary research)
• 3.6 Pipeline and clinical trials landscape
• 3.7 Impact of AI and generative AI on the market
• 3.8 Future market trends
• 3.9 Porter's analysis
• 3.10 PESTEL analysis

Chapter 4 Competitive Landscape, 2025

• 4.1 Introduction
• 4.2 Company market share analysis
  • 4.2.1 North America
  • 4.2.2 Europe
  • 4.2.3 Asia Pacific
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Key developments
  • 4.6.1 Merger and acquisition
  • 4.6.2 Partnership and collaboration
  • 4.6.3 New product launches
  • 4.6.4 Expansion plans

Chapter 5 Market Estimates and Forecast, By Drug Type, 2022 - 2035 ($ Mn)

• 5.1 Key trends
• 5.2 Aminosalicylates
• 5.3 Biologics
• 5.4 Corticosteroids
• 5.5 Janus kinase (JAK) inhibitors
• 5.6 Immunosuppressants
• 5.7 Other drug types

Chapter 6 Market Estimates and Forecast, By Disease Type, 2022 - 2035 ($ Mn)

• 6.1 Key trends
• 6.2 Proctosigmoiditis
• 6.3 Ulcerative proctitis
• 6.4 Left-sided colitis
• 6.5 Pancolitis or universal colitis
• 6.6 Fulminant colitis

Chapter 7 Market Estimates and Forecast, By Route of Administration, 2022 - 2035 ($ Mn)

• 7.1 Key trends
• 7.2 Oral
• 7.3 Injectable

Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2022 - 2035 ($ Mn)

• 8.1 Key trends
• 8.2 Hospital pharmacies
• 8.3 Retail pharmacies
• 8.4 Online pharmacies

Chapter 9 Market Estimates and Forecast, By Region, 2022 - 2035 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Italy
  • 9.3.5 Spain
  • 9.3.6 Netherlands
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 Japan
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 South Korea
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Argentina
• 9.6 Middle East and Africa
  • 9.6.1 South Africa
  • 9.6.2 Saudi Arabia
  • 9.6.3 UAE

Chapter 10 Company Profiles

• 10.1 AbbVie
• 10.2 Bausch Health Companies
• 10.3 Bristol Myers Squibb
• 10.4 Eli Lilly and Company
• 10.5 Johnson & Johnson
• 10.6 Merck
• 10.7 Mitsubishi Tanabe Pharma Corporation
• 10.8 Novartis
• 10.9 Pfizer
• 10.10 Sun Pharmaceutical Industries
• 10.11 Takeda Pharmaceutical Company Limited
• 10.12 Teva Pharmaceutical Industries